Compare AbbVie Inc (ABBV) vs Google Inc (GOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Google Inc — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Google Inc trades at $355.79 (market cap $4.46T). The key difference: Google Inc is far larger — about 9.9× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | GOOG | |
|---|---|---|
Market Cap | $449.91B | $4.46T |
Sector | Health | Technology |
52-Week High | $261.07 | $399.06 |
52-Week Low | $184.85 | $175.16 |
Enterprise Value | $513.38B | $4.42T |
Dividend Yield | 2.72% | 0.24% |
Volume | — | 1,511,127 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
GOOG trades at $363.62, up 2.09% today, reflecting strong momentum after consecutive earnings beats. The stock shows a bullish technical trend with support at $358 and resistance at $369. Revenue grew to $402.84B in 2025, with net income reaching $132.17B, driven by robust profitability margins. Recent news highlights Google's AI advancements and a dividend payment, reinforcing investor confidence.
Outlook remains positive with a consensus price target of $457.50, indicating 26% upside. Risks include competitive pressures in AI and regulatory scrutiny. Analyst sentiment is overwhelmingly bullish (86.84% buy ratings), supported by strong cash flow growth and strategic investments in fusion technology and AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
